SLU-PP-332 dosage as the literature reports it: the 50 mg/kg twice-daily intraperitoneal mouse regimen, the DMSO vehicle, the absence of any human data, and stock-solution arithmetic for a 30 mg vial.
SLU-PP-332 is not a peptide. It is a synthetic small molecule — a pan-agonist of the oestrogen-related receptors ERRα, ERRβ and ERRγ — designed in Thomas Burris's laboratory and reported in 2023 to reproduce the transcriptional signature of aerobic exercise in mouse muscle. Everything published about its dosing comes from mice, from one laboratory, by intraperitoneal injection in a DMSO-containing vehicle. There is no human pharmacokinetic study, no tolerability study and no registered trial. This page is a research reference to what those mouse studies did and to the stock-solution arithmetic for the vial size sold; it is not a protocol and not advice.
The SLU-PP-332 profile is the reference entry and the SLU-PP-332 research overview covers the nuclear-receptor biology.
Two papers carry the entire dosing record, and both come from the group that designed the compound and holds its intellectual property.
The Burris group, ACS Chemical Biology (2023). The exercise-mimetic study. Mice received SLU-PP-332 at 50 mg/kg body weight by intraperitoneal injection, twice daily, dissolved in a DMSO-containing vehicle, for a period of roughly two to four weeks; vehicle-treated controls received the same solvent on the same schedule. A single dose was used for the acute gene-expression experiments, in which the exercise-like transcriptional response appeared within hours. Treated mice ran roughly 70 percent longer and 45 percent further on a treadmill than controls, and the effect was absent in ERRα-knockout animals.
The companion study, Journal of Pharmacology and Experimental Therapeutics (2023). The same 50 mg/kg twice-daily intraperitoneal regimen in diet-induced obese mice, reporting reduced weight gain, lower fat mass, higher energy expenditure and improved glucose handling with food intake unchanged.
That is the whole list. There is no dose-ranging study, no oral or subcutaneous arm, no second species, and no exposure longer than a few weeks.
The published work describes the compound as short-lived in mice — on the order of hours — which is the stated reason for the twice-daily schedule: two injections were needed to maintain exposure across the day. No terminal half-life has been reported for any other species. For a small lipophilic molecule cleared by hepatic metabolism, human kinetics could differ from mouse kinetics by a large factor in either direction, and nothing in the record constrains the guess. That is the reason the half-life calculator on this site does not list SLU-PP-332: there is no figure to enter.
Allometric scaling is a formal method for choosing a first-in-human starting dose after toxicology, formulation and regulatory review, not a calculator for turning a mouse regimen into a protocol. Three problems are specific to SLU-PP-332. The route was intraperitoneal, which delivers the compound to the portal circulation and has no human equivalent in practice. The vehicle contained DMSO, which is itself pharmacologically active and shaped the absorption of a compound that will not dissolve in water. And no human exposure data exists to anchor either end of a scaling calculation. Anyone quoting a human SLU-PP-332 dose in milligrams is extrapolating, not citing.
SLU-PP-332 is not reconstituted the way a lyophilised peptide is. It is a lipophilic solid that will not dissolve in bacteriostatic water at useful concentrations; the published studies dissolved it in DMSO and then diluted the stock into the injection vehicle, keeping the final DMSO fraction low. The concentration arithmetic is nonetheless identical: mass ÷ solvent volume = concentration. For the SLU-PP-332 30MG vial:
The stock is the researcher's own design, and the dilution into a low-DMSO vehicle is a formulation step the papers describe and this page does not. Stock solutions are stored frozen at −20 °C in single-use aliquots; aqueous dilutions are made fresh and discarded, because the compound precipitates out of water above a low concentration. The dosing math guide and dosage calculator handle the milligram-per-millilitre conversions once a stock exists, and the vial planner turns a per-dose mass into vial usage; all three were written for peptides in bacteriostatic water, so the solvent step sits outside them. Reconstitution 101 explains the peptide method those tools assume and why it does not apply here.
SLU-PP-332 is the earliest-stage compound in this catalogue. The dosing literature is two mouse papers from one laboratory using one regimen, with a genetically confirmed mechanism and no safety work beyond noting that the animals showed no overt toxicity over a few weeks. Human pharmacokinetics, tolerability, oral bioavailability and long-term effects are unknown. The compound is not named on the WADA Prohibited List but almost certainly falls under S4.4, metabolic modulators, which prohibits related exercise mimetics by name. It has no Health Canada authorisation or DIN and is sold in Canada for laboratory research only. Where numbers on this page look precise, the precision belongs to one experimental design, not to a consensus.
What dose of SLU-PP-332 was used in the published studies? 50 mg/kg body weight by intraperitoneal injection, twice daily, in a DMSO-containing vehicle, for roughly two to four weeks in mice (the Burris group's 2023 ACS Chemical Biology and JPET papers). A single dose was used for the acute gene-expression experiments.
Is there a human dose? No. SLU-PP-332 has never been given to a human in a published study, and no pharmacokinetic or tolerability data exists from which a human figure could be derived. Mouse doses cannot be scaled without that data.
What is the half-life of SLU-PP-332? Short in mice — hours — which is why the studies dosed twice daily. It has not been measured in any other species.
How is a 30 mg vial put into solution? Not with bacteriostatic water. The solid dissolves in DMSO: 30 mg in 1 mL gives 30 mg/mL, in 3 mL gives 10 mg/mL. The published studies then diluted the stock into a low-DMSO vehicle for injection. Stock solutions are frozen in aliquots and aqueous dilutions made fresh.
Is SLU-PP-332 a peptide? No. It is a lipophilic organic small molecule with no amino-acid sequence. It is stocked beside MOTS-c because both are studied around mitochondrial function, not because they handle alike.
Is this medical advice? No. This page describes what published mouse studies did, for laboratory reference. SLU-PP-332 is sold here as a research-grade material, not for human or veterinary use, and nothing above is a protocol, a dosing recommendation or a safety assurance.
